The latest edition of the Catabasis Connection newsletter discusses Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Read the full newsletter here.
With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have launched. Sites are also expected to launch soon in Europe and Israel.
We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by NS Pharma and look forward to continued success. NS Pharma Community Letter
Dear Duchenne Advocacy Leaders, Lately we have heard many stop to consider the progress made in the last decade in Duchenne treatment and care. Improvements have been driven by this community – by you – and organization around key topics like care considerations and standards of care, a topic well chosen for this year’s World […]